OpenAI's Miles Wang in Talks for $2B AI Drug-Discovery Debut
TL;DR
- Wang joined OpenAI in 2024 after leaving Harvard; the $2B founding valuation is a bet on lab pedigree with under two years of frontier-AI experience.
- Wang publicly disputed TechCrunch's funding figures and company description but declined to provide corrected numbers, leaving core deal terms unverified.
- Multiple OpenAI colleagues are expected to join, marking a team exit rather than a solo departure and amplifying the talent-drain signal for the lab.
An OpenAI researcher barely two years into the job is reportedly in talks to leave with a $2 billion founding valuation attached to his name, and that is the part that keeps standing out. According to TechCrunch, Miles Wang, who joined OpenAI in 2024 after dropping out from Harvard where he was working on a bachelor's degree in computer science, is in talks to raise about $200 million for an AI drug discovery startup, with Lightspeed in discussions to lead the round.
The pitch, as reported, is applying the kind of models Wang worked on at OpenAI, where he co-authored research on evaluating how AI models can automate and accelerate scientific discovery, to biology. Early focus areas may include finding new uses for existing drugs and compounds that previously failed in trials. Several other OpenAI researchers are expected to join the new company. That is a meaningful detail: this is not a solo departure but a small team lift, and OpenAI's science-adjacent bench is what is being drained.
Why this matters if you are not in venture or in pharma: a company with no product and no clinical data is reportedly clearing a $2 billion valuation on the strength of its founder's OpenAI lineage and thesis. That is the same pattern investors paid for at Chai Discovery, which announced a $400 million round at a $3.8 billion valuation this week. Frontier labs are turning into founder factories, and the price of the pedigree is climbing.
The honest caveat is that Wang disputed the reported funding figures and description of the company without specifying corrected numbers, and TechCrunch itself notes the talks are ongoing and details could change. What the reporting does not give you is who the other researchers are, what data the company plans to train on, or how OpenAI is reacting to the exodus. The upside, if it holds, is a well-capitalized team pointed at drug repurposing, which has a shorter path to revenue than developing new molecules from scratch, and one more data point that AI-for-bio is where the next wave of talent and money is heading.
What others are reporting
-
The Next Web Read →
Frames investor enthusiasm against the harder unsolved problem: clinical trials take a decade, cost ~$2.7B, and fail 90%+ of the time regardless of AI advances in molecular design.
Drug discovery is a 'lighter' problem in the food chain of bringing a drug to market. The harder problem is making drugs succeed in clinical trials.
Originally reported by techcrunch.com
Read the original article →Original headline: OpenAI Drug-Discovery Researcher Miles Wang Leaves to Launch Startup at $2B — In Talks to Raise $200M Led by Lightspeed, Several OpenAI Colleagues Expected to Follow